guest column

Houston fintech founder: It's time to rewire our digital infrastructure

If the last few weeks have shown us anything, it's how important the resilience of our digital infrastructure is, our reliance on data, and the power technology has to help us during challenging times. Getty Images

As the United States looks to reopen from an unprecedented shutdown caused by a global pandemic, conversations amongst government and policy bodies are slowly switching to how they will support the economy in the long term. There is a need to improve infrastructure, strengthen the supply chain, increase economic resiliency, etc.

Indeed, the speed of the economic shock caused by COVID-19 highlighted the fragility of many key systems and processes, impacting the ability of the federal and state governments to distribute economic relief funds, manage healthcare capacity, and support small businesses.

There is no better illustration of this fragility in the system than the sudden spike in demand for COBOL programmers. COBOL is a decades-old programming language that was used to write mainframe applications. Apparently over half of the states in the U.S., including California and New York, rely on applications written in a language first introduced in 1959 for their critical state systems.

There is clearly a need to modernize the public services technology infrastructure, not only in expectation of future pandemic-driven disruptions but to increase efficiency and reduce costs nationally. The private sector can and should play an important role in bringing modern technology into the critical parts of the economy.

But that requires a closer collaboration between state governments and technology firms to identify the best and most efficient way forward. Technologies such as artificial intelligence, blockchain, and the Internet of Things can dramatically reshape and improve public sector technology infrastructure while providing broader benefits to the state economies.

The critical first step in building this public-private partnership is to educate and engage state officials and legislators on specific technologies that can be put to use.

On April 29, I attended a virtual meeting organized by Texas Blockchain Committee (TBC) and hosted by the office of State Representative Tan Parker. In attendance, there were individuals and organizations based in Texas that are involved in developing practical applications of blockchain technology. What was also encouraging was that there were quite a few members of the State Legislature in attendance.

Here are a few key points that are worth highlighting from the meeting:

  • There is growing recognition and acceptance that blockchain is a technology that has wide applications outside of the cryptocurrency world. In fact, during the meeting, no one mentioned Bitcoin or crypto-trading.
  • Texas is aiming to explore ways to be at the forefront of blockchain technology adoption and be the leader among the states in promoting Blockchain innovation. Back in 2018 at the height of ICO and cryptocurrency mania, The Brooking Institution labeled Texas as reactionary when it comes to blockchain. Since then the state attitude has changed, in many ways thanks to Representative Parker and his push to initiate a proper study of blockchain's applicability at the state level.
  • There are many Texas-based companies with deep technical expertise and know-how in the blockchain. Some even moved their operations from other parts of the country to Texas in order to scale their businesses.
  • Whether it is related to the distribution of relief funds for businesses or individuals impacted by COVID -19, improvements in the way the healthcare industry handles patient data or other areas that require secure and transparent record management, blockchain is gaining attention as a technology to modernize critical digital infrastructure.
  • Particular attention was given to the efforts in other countries to bring blockchain technology into mainstream adoption. For example, China launched its nationwide Blockchain Services Network (BSN) in April of this year and is looking to bring digital central bank currency online early next year. The Chinese BSN is a result of joint efforts by the government, regulators, and private sector companies – a model that could work very well in the U.S. and in Texas.
  • It is worth noting that at the federal level there are currently over 30 blockchain-related bills in the U.S. House of Representatives and Senate. While a majority of these bills are focusing on the regulation of cryptocurrencies, there are a few that aim to promote the study of blockchain usage more broadly.

As a Texas-based fintech company that has been using Blockchain for the past three years, we are very encouraged by the broad interest in this technology. The Texas Blockchain Committee, led by Lee Bratcher and Karen Kilroy, has managed to pull together many individuals and companies to participate in this exciting effort.

If the last few weeks have shown us anything, it's how important the resilience of our digital infrastructure is, our reliance on data, and the power technology has to help us during challenging times. However, in order for us to leverage technology during harder times, we need to invest in properly applying it during stable times.

I believe this is a step in the right direction for Texas, and I hope we are able to expand the adoption of this technology, where relevant, at a national level. A coordinated national effort to study how technology, blockchain or otherwise, can help us be better prepared for our country's future.

------

Rashad Kurbanov is the CEO and co-founder of Houston-based iownit capital and markets, a digital investment platform for private securities.

Trending News

Building Houston

 
 

Allterum Therapeutics Inc., a portfolio company of Fannin Innovation Studio, is using the funds to prepare for clinical trials. Photo via Getty Images

Allterum Therapeutics Inc. has built a healthy launchpad for clinical trials of an immunotherapy being developed to fight a rare form of pediatric cancer.

The Houston startup recently collected $1.8 million in seed funding through an investor group associated with Houston-based Fannin Innovation Studio, which focuses on commercializing biotech and medtech discoveries. Allterum has also brought aboard pediatric oncologist Dr. Philip Breitfeld as its chief medical officer. And the startup, a Fannin spinout, has received a $2.9 million grant from the Cancer Prevention Research Institute of Texas.

The funding and Breitfeld's expertise will help Allterum prepare for clinical trials of 4A10, a monoclonal antibody therapy for treatment of cancers that "express" the interleukin-7 receptor (IL7R) gene. These cancers include pediatric acute lymphoblastic leukemia (ALL) and some solid-tumor diseases. The U.S. Food and Drug Administration (FDA) has granted "orphan drug" and "rare pediatric disease" designations to Allterum's monoclonal antibody therapy.

If the phrase "monoclonal antibody therapy" sounds familiar, that's because the FDA has authorized emergency use of this therapy for treatment of COVID-19. In early January, the National Institute of Allergy and Infectious Diseases announced the start of a large-scale clinical trial to evaluate monoclonal antibody therapy for treatment of mild and moderate cases of COVID-19.

Fannin Innovation Studio holds exclusive licensing for Allterum's antibody therapy, developed at the National Cancer Institute. Aside from the cancer institute, Allterum's partners in advancing this technology include the Therapeutic Alliance for Children's Leukemia, Baylor College of Medicine, Texas Children's Hospital, Children's Oncology Group, and Leukemia & Lymphoma Society.

Although many pediatric patients with ALL respond well to standard chemotherapy, some patients continue to grapple with the disease. In particular, patients whose T-cell ALL has returned don't have effective standard therapies available to them. Similarly, patients with one type of B-cell ALL may not benefit from current therapies. Allterum's antibody therapy is designed to effectively treat those patients.

Later this year, Allterum plans to seek FDA approval to proceed with concurrent first- and second-phase clinical trials for its immunotherapy, says Dr. Atul Varadhachary, managing partner of Fannin Innovation Studio, and president and CEO of Allterum. The cash Allterum has on hand now will go toward pretrial work. That will include the manufacturing of the antibody therapy by Japan's Fujifilm Diosynth Biotechnologies, which operates a facility in College Station.

"The process of making a monoclonal antibody ready to give to patients is actually quite expensive," says Varadhachary, adding that Allterum will need to raise more money to carry out the clinical trials.

The global market for monoclonal antibody therapies is projected to exceed $350 billion by 2027, Fortune Business Insight says. The continued growth of these products "is expected to be a major driver of overall biopharmaceutical product sales," according to a review published last year in the Journal of Biomedical Science.

One benefit of these antibody therapies, delivered through IV-delivered infusions, is that they tend to cause fewer side effects than chemotherapy drugs, the American Cancer Society says.

"Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. They are designed to bind to antigens that are generally more numerous on the surface of cancer cells than healthy cells," the Mayo Clinic says.

Varadhachary says that unlike chemotherapy, monoclonal antibody therapy takes aim at specific targets. Therefore, monoclonal antibody therapy typically doesn't broadly harm healthy cells the way chemotherapy does.

Allterum's clinical trials initially will involve children with ALL, he says, but eventually will pivot to children and adults with other kinds of cancer. Varadhachary believes the initial trials may be the first cancer therapy trials to ever start with children.

"Our collaborators are excited about that because, more often than not, the cancer drugs for children are ones that were first developed for adults and then you extend them to children," he says. "We're quite pleased to be able to do something that's going to be important to children."

Trending News